Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

Conclusion:
Increased CSF levels of sTREM-2, a new marker of microglial activation, in MS and normalization upon treatment with either natalizumab or mitoxantrone support a role for microglial activation in active MS.

Source: Multiple Sclerosis - October 13, 2016 Category: Neurology Authors: Öhrfelt, A., Axelsson, M., Malmeström, C., Novakova, L., Heslegrave, A., Blennow, K., Lycke, J., Zetterberg, H. Tags: Original Research Papers Source Type: research